Final Results From the 16‐Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry

@article{Ephross2014FinalRF,
  title={Final Results From the 16‐Year Sumatriptan, Naratriptan, and Treximet Pregnancy Registry},
  author={Sara A. Ephross and Susan M. Sinclair},
  journal={Headache: The Journal of Head and Face Pain},
  year={2014},
  volume={54}
}
To monitor for a signal of major teratogenicity by determining the risk of all birth major defects following in utero exposure to sumatriptan, naratriptan, and the sumatriptan/naproxen sodium combination product (tablets marketed in the United States as Treximet [GlaxoSmithKline, Research Triangle Park, NC, USA]), and to monitor for unusual patterns of defects that might suggest teratogenicity. 
Sumatriptan
Sumatriptan (Imitrex®, Imigran®) is a medication used to treat migraine headaches. It can be used orally (pill), by nasal spray or by injection (shot). Sumatriptan is also available in a combination
Sumatriptan
  • Medicine
    Reactions Weekly
  • 2020
Sumatriptan (Imitrex®, Imigran®) is a medication used to treat migraine headaches. It can be used orally (pill), by nasal spray or by injection (shot). Sumatriptan is also available in a combination
Sumatriptan
Sumatriptan (Imitrex®, Imigran®) is a medication used to treat migraine headaches. It can be used orally (pill), by nasal spray or by injection (shot). Sumatriptan is also available in a combination
Sumatriptan
Sumatriptan (Imitrex®, Imigran®) is a medication used to treat migraine headaches. It can be used orally (pill), by nasal spray or by injection (shot). Sumatriptan is also available in a combination
Sumatriptan
  • Medicine
    Reactions Weekly
  • 2020
Sumatriptan (Imitrex®, Imigran®) is a medication used to treat migraine headaches. It can be used orally (pill), by nasal spray or by injection (shot). Sumatriptan is also available in a combination
Maternal Use of Drugs for Migraine and Infant Congenital Malformations
  • B. Källén
  • Medicine
    Maternal Drug Use and Infant Congenital Malformations
  • 2019
TLDR
Little is known on the use of pizotifen during pregnancy and available data do not indicate a teratogenic risk but more information is needed.
Pregnancy Outcome Following Prenatal Exposure to Triptan Medications: A Meta‐Analysis
TLDR
The reproductive safety of triptan medications was determined by performing a literature review and a meta‐analysis of existing studies on the use of these medications in women of childbearing age.
Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study
TLDR
The findings support the evidence that triptans are not major teratogens and a detailed fetal ultrasound should be offered in cases of first trimester exposure to less well-studied triptan.
Schwangere können Triptane nehmen
  • H. Diener
  • Medicine
    MMW - Fortschritte der Medizin
  • 2014
Obwohl Triptane in Tierexperimenten nicht teratogen sind, sind sie bis heute in der Schwangerschaft kontraindiziert. Das sollte sich angesichts neuer Daten bald ändern.
Neurological disease in pregnancy
...
...

References

SHOWING 1-10 OF 50 REFERENCES
Pregnancy Outcome Following Prescription for Sumatriptan
TLDR
The aim of this study was to examine the association between sumatriptan exposure during pregnancy and the risk of preterm delivery and low birth weight.
Pregnancy outcome following first trimester exposure to sumatriptan
TLDR
This first prospective report suggests that the use of sumatriptan during organogenesis is not associated with an apparent increased risk of major birth defects.
Final results from 18 years of the International Lamotrigine Pregnancy Registry
TLDR
With over 1,500 first-trimester monotherapy exposures, the Registry was powered to detect major teratogenicity and failed to observe an increased MCM frequency with increasing lamotrigine dose.
Evidence‐Based Assessment of Pregnancy Outcome After Sumatriptan Exposure
TLDR
Assessment of best available evidence for tolerability of sumatriptan after inadvertent exposure during pregnancy finds it to be safe and feasible to use during pregnancy.
Monitoring birth outcomes in the Sumatriptan Pregnancy Registry.
Nonsteroidal anti-inflammatory drugs in early pregnancy.
Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study
TLDR
Perinatal and pregnancy outcome did not differ between patients who had and had not used sumatriptan after conception, at the resolution of these sample sizes.
Increased rate of major malformations in offspring exposed to valproate during pregnancy
TLDR
Maternal exposure to valproic acid during the first trimester of pregnancy significantly increased the risk of major malformations in infants whose mothers had taken the drug VPA as monotherapy and had enrolled in the North American Antiepileptic Drug Pregnancy Registry.
Systematic identification of drugs that cause birth defects--a new opportunity.
  • A. Mitchell
  • Medicine
    The New England journal of medicine
  • 2003
Patients, prescribers, and policymakers often assume that the most serious short-term adverse effects of a drug are identified in pre-marketing studies, so recognition of unexpected harm after
...
...